The Effectiveness, Tolerability, and Safety of Different 1-Day Bowel Preparation Regimens for Pediatric Colonoscopy

Table 2

Safety of three bowel cleansing regimens.

Adverse event	PEG-bisacodyl group,	PEG-ELS group,	NaPico+MgCit group,	All groups,
Overall	25 (61%)	30 (69.8%)	18 (46.2%)	73 (59.3%)
Abdominal pain	13 (31.7%)	16 (37.2%)	13 (33.3%)	42 (34.1%)	NS
Nausea	7 (17.1%)	8 (18.6%)	0 (0%)	15 (12.2%)
Vomiting	6 (14.6%)	4 (9.3%)	2 (5.1%)	12 (9.8%)	NS
Flatulence	4 (9.8%)	4 (9.3%)	0 (0%)	8 (6.5%)	NS
Perianal discomfort/pain	8 (19.5%)	3 (7%)	4 (10.3%)	15 (12.2%)	NS
Sleep disturbance	14 (34.1%)	16 (37.2%)	16 (37.2%)	7 (17.9%)	NS
Dizziness	7 (17.1%)	3 (7.0%)	1 (2.6%)	11 (8.9%)	NS
Apathy	9 (22.2%)	5 (11.6%)	2 (5.1%)	16 (13.0%)
Others	2 (4.9%)	2 (4.7%)	2 (5.1%)	6 (4.9%)	NS

NS = statistically nonsignificant; PEG-bisacodyl vs. PEG-ELS: , PEG-bisacodyl vs. NaPico+MgCit: , and PEG-ELS vs. NaPico+MgCit: ; PEG-bisacodyl vs. PEG-ELS: , PEG-bisacodyl vs. NaPico+MgCit: , and PEG-ELS vs. NaPico+MgCit: ; PEG-bisacodyl vs. PEG-ELS: , PEG-bisacodyl vs. NaPico+MgCit: , and PEG-ELS vs. NaPico+MgCit: .